Trials / Unknown
UnknownNCT03714568
Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.
Pharmacokinetic and Tolerance Study in Healthy Participants: a Single-centre, Randomized, Double-blind, Placebo-controlled Trial
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
To study the single dose and multi-doses pharmacokinetic characteristics and tolerance of TQ-A3326 in the human body；To study the transformation of TQ-A3326；To study the effect of the food on the pharmacokinetic characteristics of TQ-A3326.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-A3326 | TQ-A3326 (15mg-180mg: p.o. single dose; 60mg: p.o. multi-doses） |
| DRUG | placebo | Placebo(15-180mg: p.o. single dose; 60mg: p.o. multi-doses) |
Timeline
- Start date
- 2018-11-11
- Primary completion
- 2019-09-01
- Completion
- 2019-09-01
- First posted
- 2018-10-22
- Last updated
- 2018-12-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03714568. Inclusion in this directory is not an endorsement.